Treatment of adults Ph+ALL with dasatinb in induction and maintenance therathpy followed by allogeneic hematopoietic stem cell transplantation

Treatment of adults Ph+ALL with dasatinb in induction and maintenance therathpy followed by allogeneic HSCT: a multicenter, no controll, prospective stduy.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-OIC-17010852

Enrollment

Unknown

Registered

2017-03-13

Start date

2017-03-13

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Philadelphia chromosome positive acute lymphoblastic leukemia

Interventions

Experimental group:Dasatinb and hematopoietic stenm cell transplantation

Eligibility

Sex/Gender

All

Age

14 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Male or Female, aged 14 to 60 years; 2. ECOG performance status of <= 2 at study entry witout the disfunction of important organs; 3. Understand and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Serious systemic organ dysfunction; 2. Patient with malignant tumor that needs to be treated; 3.The patients with clinical symptom of brain dysfunction or serious psychiosis that can't understand or obey the study; 4. Patients that can't followed up as scheduled; 5. Patients that can't guarantee complete the plan and follow up.

Design outcomes

Secondary

Measure	Time frame
The 2-year overall survival;Time of recovery;Rate of GVHD;Non-relapse mortality;Rate of relpase;	—

Primary

Measure	Time frame
The 2-year disease-free survival;	—

Countries

China

Contacts

Public ContactZhang Cheng

Department of hematology, the Third Military Medical Universtiy

chzhang2014@163.com+86 13098770350

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026